Zeitschriftenartikel zum Thema „Irreversible inhibitor“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Irreversible inhibitor" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Buneeva, O. A., L. N. Aksenova und A. E. Medvedev. „A Simple Approach for Pilot Analysis of Time-dependent Enzyme Inhibition: Discrimination Between Mechanism-based Inactivation and Tight Binding Inhibitor Behavior“. Biomedical Chemistry: Research and Methods 3, Nr. 1 (2020): e00115. http://dx.doi.org/10.18097/bmcrm00115.
Der volle Inhalt der QuelleGledhill, L., P. Williams und B. W. Bycroft. „Irreversible inactivation of β-lactamase I from Bacillus cereus by chlorinated 6-spiroepoxypenicillins“. Biochemical Journal 276, Nr. 3 (15.06.1991): 801–7. http://dx.doi.org/10.1042/bj2760801.
Der volle Inhalt der QuelleRožman, Kaja, Evan M. Alexander, Eva Ogorevc, Krištof Bozovičar, Izidor Sosič, Courtney C. Aldrich und Stanislav Gobec. „Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome“. Molecules 25, Nr. 6 (12.03.2020): 1305. http://dx.doi.org/10.3390/molecules25061305.
Der volle Inhalt der QuelleMorgan, Hugh P., Martin J. Walsh, Elizabeth A. Blackburn, Martin A. Wear, Matthew B. Boxer, Min Shen, Henrike Veith et al. „A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase“. Biochemical Journal 448, Nr. 1 (18.10.2012): 67–72. http://dx.doi.org/10.1042/bj20121014.
Der volle Inhalt der QuelleVerdugo, Anael, P. K. Vinod, John J. Tyson und Bela Novak. „Molecular mechanisms creating bistable switches at cell cycle transitions“. Open Biology 3, Nr. 3 (März 2013): 120179. http://dx.doi.org/10.1098/rsob.120179.
Der volle Inhalt der QuelleViczjan, Gabor, Tamas Erdei, Ignac Ovari, Nora Lampe, Reka Szekeres, Mariann Bombicz, Barbara Takacs et al. „A Body of Circumstantial Evidence for the Irreversible Ectonucleotidase Inhibitory Action of FSCPX, an Agent Known as a Selective Irreversible A1 Adenosine Receptor Antagonist So Far“. International Journal of Molecular Sciences 22, Nr. 18 (11.09.2021): 9831. http://dx.doi.org/10.3390/ijms22189831.
Der volle Inhalt der QuelleKondža, Martin, Mirza Bojić, Ivona Tomić, Željan Maleš, Valentina Rezić und Ivan Ćavar. „Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids“. Molecules 26, Nr. 10 (19.05.2021): 3018. http://dx.doi.org/10.3390/molecules26103018.
Der volle Inhalt der QuelleEspín, J. C., und J. Tudela. „Experimental approach to the kinetic study of unstable site-directed irreversible inhibitors: kinetic origin of the apparent positive co-operativity arising from inactivation of trypsin by p-amidinophenylmethanesulphonyl fluoride“. Biochemical Journal 299, Nr. 1 (01.04.1994): 29–35. http://dx.doi.org/10.1042/bj2990029.
Der volle Inhalt der QuelleBitonti, A. J., P. J. Casara, P. P. McCann und P. Bey. „Catalytic irreversible inhibition of bacterial and plant arginine decarboxylase activities by novel substrate and product analogues“. Biochemical Journal 242, Nr. 1 (15.02.1987): 69–74. http://dx.doi.org/10.1042/bj2420069.
Der volle Inhalt der QuelleLiyanage, Piyumi Dinusha, Pabudi Weerathunge, Mandeep Singh, Vipul Bansal und Rajesh Ramanathan. „L-Cysteine as an Irreversible Inhibitor of the Peroxidase-Mimic Catalytic Activity of 2-Dimensional Ni-Based Nanozymes“. Nanomaterials 11, Nr. 5 (13.05.2021): 1285. http://dx.doi.org/10.3390/nano11051285.
Der volle Inhalt der QuelleMay, Earl, Daniel Urul, Khanh Huynh, Susan Cornell-Kennon, Venkatesh Nemmara, Zhibing Lu, Samuel Hoare, Michelle Lyles und Erik Schaefer. „Abstract 2061: A proven activity-based workflow for the identification and characterization of time-dependent kinase inhibitors using a continuous assay format“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 2061. http://dx.doi.org/10.1158/1538-7445.am2024-2061.
Der volle Inhalt der QuelleHan, Chun, Jiahong Ren, Feng Su, Xiaoqin Hu, Mengyao Li, Zhijun Wang und Lintao Wu. „Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines“. Anti-Cancer Agents in Medicinal Chemistry 20, Nr. 6 (14.06.2020): 724–33. http://dx.doi.org/10.2174/1871520620666200302113206.
Der volle Inhalt der QuelleTikhonova, O. V., V. S. Skvortsov und O. A. Raevsky. „Molecular modeling of acetylcholinesterase interaction with irreversible and reversible organophosphorous inhibitors“. Biomeditsinskaya Khimiya 57, Nr. 1 (Januar 2011): 61–76. http://dx.doi.org/10.18097/pbmc20115701061.
Der volle Inhalt der QuellePoole, R. C., und A. P. Halestrap. „Reversible and irreversible inhibition, by stilbenedisulphonates, of lactate transport into rat erythrocytes. Identification of some new high-affinity inhibitors“. Biochemical Journal 275, Nr. 2 (15.04.1991): 307–12. http://dx.doi.org/10.1042/bj2750307.
Der volle Inhalt der QuelleYu, Xiangfan, Simei Qiu, Dongshan Sun, Pei Guo und Quhuan Li. „Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations“. Molecules 27, Nr. 21 (02.11.2022): 7451. http://dx.doi.org/10.3390/molecules27217451.
Der volle Inhalt der QuelleBastlein, C., und G. Burckhardt. „Sensitivity of rat renal luminal and contraluminal sulfate transport systems to DIDS“. American Journal of Physiology-Renal Physiology 250, Nr. 2 (01.02.1986): F226—F234. http://dx.doi.org/10.1152/ajprenal.1986.250.2.f226.
Der volle Inhalt der QuelleKETTLE, Anthony J., Craig A. GEDYE und Christine C. WINTERBOURN. „Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide“. Biochemical Journal 321, Nr. 2 (15.01.1997): 503–8. http://dx.doi.org/10.1042/bj3210503.
Der volle Inhalt der QuelleRobak, Ewa, und Tadeusz Robak. „Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives“. Journal of Clinical Medicine 11, Nr. 10 (16.05.2022): 2807. http://dx.doi.org/10.3390/jcm11102807.
Der volle Inhalt der QuelleWILLIAMS, CARVELL H., und BRENDA BELSHAW. „An iodinated, irreversible inhibitor of monoamine oxidase“. Biochemical Society Transactions 13, Nr. 2 (01.04.1985): 469–70. http://dx.doi.org/10.1042/bst0130469.
Der volle Inhalt der QuelleKindler, Hedy L., und Richard L. Schilsky. „Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase“. Expert Opinion on Investigational Drugs 9, Nr. 7 (Juli 2000): 1635–49. http://dx.doi.org/10.1517/13543784.9.7.1635.
Der volle Inhalt der QuelleSchaschke, Norbert, Dominga Deluca, Irmgard Assfalg-Machleidt, Clara Höhneke, Christian P. Sommerhoff und Werner Machleidt. „Epoxysuccinyl Peptide-Derived Cathepsin B Inhibitors: Modulating Membrane Permeability by Conjugation with the C-Terminal Heptapeptide Segment of Penetratin“. Biological Chemistry 383, Nr. 5 (15.05.2002): 849–52. http://dx.doi.org/10.1515/bc.2002.090.
Der volle Inhalt der QuelleTipton, K. F., J. M. McCrodden und M. B. Youdim. „Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)“. Biochemical Journal 240, Nr. 2 (01.12.1986): 379–83. http://dx.doi.org/10.1042/bj2400379.
Der volle Inhalt der QuelleGreenspan, M. D., H. G. Bull, J. B. Yudkovitz, D. P. Hanf und A. W. Alberts. „Inhibition of 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis by β-lactone inhibitors and binding of these inhibitors to the enzyme“. Biochemical Journal 289, Nr. 3 (01.02.1993): 889–95. http://dx.doi.org/10.1042/bj2890889.
Der volle Inhalt der QuelleRobak, Tadeusz, Magda Witkowska und Piotr Smolewski. „The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions“. Cancers 14, Nr. 3 (02.02.2022): 771. http://dx.doi.org/10.3390/cancers14030771.
Der volle Inhalt der QuelleLaw, Brian, Daniel Lu, Priyanka Somanath, James T. Palmer, Taisei Kinoshita und Thomas Butler. „Abstract 2665: Irreversible menin inhibitor, BMF-219, inhibits the growth of KRAS-mutated solid tumors“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 2665. http://dx.doi.org/10.1158/1538-7445.am2022-2665.
Der volle Inhalt der QuelleBridges, A. J. „The Rationale and Strategy Used to Develop a Series of Highly Potent, Irreversible, Inhibitors of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases“. Current Medicinal Chemistry 6, Nr. 9 (September 1999): 825–43. http://dx.doi.org/10.2174/092986730609220401151141.
Der volle Inhalt der QuelleHashimoto, Yoshitami, und Hirofumi Tanaka. „Mre11 exonuclease activity promotes irreversible mitotic progression under replication stress“. Life Science Alliance 5, Nr. 6 (15.03.2022): e202101249. http://dx.doi.org/10.26508/lsa.202101249.
Der volle Inhalt der QuelleNakatani, Toshiyuki, Ken Uda, Takeshi Yamaura, Masaru Takasaki, Akimi Akashi, Fangli Chen, Yuichi Ishikawa et al. „Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations“. Blood 126, Nr. 23 (03.12.2015): 1353. http://dx.doi.org/10.1182/blood.v126.23.1353.1353.
Der volle Inhalt der QuelleBoudier, C., und J. G. Bieth. „Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor“. Biochemical Journal 303, Nr. 1 (01.10.1994): 61–68. http://dx.doi.org/10.1042/bj3030061.
Der volle Inhalt der QuelleLombardi, Paolo. „The Irreversible Inhibition of Aromatase (Oestrogen Synthetase) by Steroidal Compounds“. Current Pharmaceutical Design 1, Nr. 1 (Juni 1995): 23–50. http://dx.doi.org/10.2174/1381612801666220524190226.
Der volle Inhalt der QuelleGantt, Soren M., Joon Mo Myung, Marcelo R. S. Briones, Wei Dong Li, E. J. Corey, Satoshi Omura, Victor Nussenzweig und Photini Sinnis. „Proteasome Inhibitors Block Development ofPlasmodium spp“. Antimicrobial Agents and Chemotherapy 42, Nr. 10 (01.10.1998): 2731–38. http://dx.doi.org/10.1128/aac.42.10.2731.
Der volle Inhalt der QuelleZeng, Qingbei, Anilkumar G. Nair, Stuart B. Rosenblum, Hsueh-Cheng Huang, Charles A. Lesburg, Yueheng Jiang, Oleg Selyutin et al. „Discovery of an irreversible HCV NS5B polymerase inhibitor“. Bioorganic & Medicinal Chemistry Letters 23, Nr. 24 (Dezember 2013): 6585–87. http://dx.doi.org/10.1016/j.bmcl.2013.10.060.
Der volle Inhalt der QuelleLawyer, Arthur L., Sarita R. Kelley und Judith I. Allen. „Use of Pyruvate-Phosphate Dikinase as a Target for Herbicide Design: Analysis of Inhibitor Specificity“. Zeitschrift für Naturforschung C 42, Nr. 6 (01.06.1987): 834–36. http://dx.doi.org/10.1515/znc-1987-0633.
Der volle Inhalt der QuelleLawyer, Arthur L., Sarita R. Kelley und Judith I. Allen. „Use of Pyruvate-Phosphate Dikinase as a Target for Herbicide Design: Analysis of Inhibitor Specificity“. Zeitschrift für Naturforschung C 42, Nr. 7-8 (01.08.1987): 834–36. http://dx.doi.org/10.1515/znc-1987-7-816.
Der volle Inhalt der QuelleBarrand, M. A., und B. A. Callingham. „The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Its use as a radioactive ligand for the enzyme“. Biochemical Journal 232, Nr. 2 (01.12.1985): 415–23. http://dx.doi.org/10.1042/bj2320415.
Der volle Inhalt der QuelleMaryška, Michal, Lucie Svobodová, Wim Dehaen, Martina Hrabinová, Michaela Rumlová, Ondřej Soukup und Martin Kuchař. „Heterocyclic Cathinones as Inhibitors of Kynurenine Aminotransferase II—Design, Synthesis, and Evaluation“. Pharmaceuticals 14, Nr. 12 (10.12.2021): 1291. http://dx.doi.org/10.3390/ph14121291.
Der volle Inhalt der QuelleZhang, Datong, He Gong und Fancui Meng. „Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases“. Molecules 26, Nr. 16 (13.08.2021): 4907. http://dx.doi.org/10.3390/molecules26164907.
Der volle Inhalt der QuelleHopkins, Michael, John J. Tyson und Béla Novák. „Cell-cycle transitions: a common role for stoichiometric inhibitors“. Molecular Biology of the Cell 28, Nr. 23 (07.11.2017): 3437–46. http://dx.doi.org/10.1091/mbc.e17-06-0349.
Der volle Inhalt der QuelleLee, Eun, Hyewon Cho, Da Kyung Lee, JuHyun Ha, Byeong Jo Choi, Ji Hye Jeong, Jae-Ha Ryu, Jong Soon Kang und Raok Jeon. „Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase“. International Journal of Molecular Sciences 21, Nr. 21 (28.10.2020): 8006. http://dx.doi.org/10.3390/ijms21218006.
Der volle Inhalt der QuelleBrullo, Chiara, Carla Villa, Bruno Tasso, Eleonora Russo und Andrea Spallarossa. „Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective“. International Journal of Molecular Sciences 22, Nr. 14 (16.07.2021): 7641. http://dx.doi.org/10.3390/ijms22147641.
Der volle Inhalt der QuelleHe, Ran, Kyoungsook Park, Hongyi Cai, Arun Kapoor, Michael Forman, Bryan Mott, Gary H. Posner und Ravit Arav-Boger. „Artemisinin-Derived Dimer Diphenyl Phosphate Is an Irreversible Inhibitor of Human Cytomegalovirus Replication“. Antimicrobial Agents and Chemotherapy 56, Nr. 7 (30.04.2012): 3508–15. http://dx.doi.org/10.1128/aac.00519-12.
Der volle Inhalt der QuellePenning, T. M. „Irreversible inhibition of Δ5-3-oxosteroid isomerase by 2-substituted progesterones“. Biochemical Journal 226, Nr. 2 (01.03.1985): 469–76. http://dx.doi.org/10.1042/bj2260469.
Der volle Inhalt der QuellePark, Jong-Hyun, Yeon Ha Ju, Ji Won Choi, Hyo Jung Song, Bo Ko Jang, Junsung Woo, Heejung Chun et al. „Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease“. Science Advances 5, Nr. 3 (März 2019): eaav0316. http://dx.doi.org/10.1126/sciadv.aav0316.
Der volle Inhalt der QuelleSteverding, Dietmar. „On the Reversible and Irreversible Inhibition of Rhodesain by Curcumin“. Molecules 25, Nr. 1 (30.12.2019): 143. http://dx.doi.org/10.3390/molecules25010143.
Der volle Inhalt der QuelleLighezan, Rodica, Adrian Sturza, Oana M. Duicu, Raluca A. Ceausu, Adrian Vaduva, Marian Gaspar, Horea Feier et al. „Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease“. Canadian Journal of Physiology and Pharmacology 94, Nr. 10 (Oktober 2016): 1040–47. http://dx.doi.org/10.1139/cjpp-2015-0580.
Der volle Inhalt der QuelleSchröder, Martin, Panagis Filippakopoulos, Martin P. Schwalm, Carla A. Ferrer, David H. Drewry, Stefan Knapp und Apirat Chaikuad. „Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3“. International Journal of Molecular Sciences 21, Nr. 21 (26.10.2020): 7953. http://dx.doi.org/10.3390/ijms21217953.
Der volle Inhalt der QuelleHarris, Christopher M., Sage E. Foley, Eric R. Goedken, Mark Michalak, Sara Murdock und Noel S. Wilson. „Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase“. SLAS DISCOVERY: Advancing the Science of Drug Discovery 23, Nr. 10 (10.07.2018): 1040–50. http://dx.doi.org/10.1177/2472555218787445.
Der volle Inhalt der QuelleKuhn, Deborah J., Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fred W. van Leeuwen und Robert Z. Orlowski. „The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.“ Blood 108, Nr. 11 (16.11.2006): 3461. http://dx.doi.org/10.1182/blood.v108.11.3461.3461.
Der volle Inhalt der QuelleChung, Vincent, Ling Wang, Margaret S. Fletcher, Erminia Massarelli, Karen L. Reckamp, Mihaela C. Cristea, Nikeeta Prajapati et al. „First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma.“ Journal of Clinical Oncology 37, Nr. 15_suppl (20.05.2019): TPS3146. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps3146.
Der volle Inhalt der QuelleLiclican, Albert, Weimei Xing, Loredana Serafini, Ting Wang, Kathy Brendza, Justin Lutz, Adrian S. Ray, Brian Schultz, Roman Sakowicz und Joy Y. Feng. „Biochemical Characterization of GS-4059 As a Potent and Selective Covalent Irreversible Inhibitor of Bruton's Tyrosine Kinase“. Blood 128, Nr. 22 (02.12.2016): 1594. http://dx.doi.org/10.1182/blood.v128.22.1594.1594.
Der volle Inhalt der Quelle